Skip to main content
. Author manuscript; available in PMC: 2013 Dec 17.
Published in final edited form as: Asia Pac J Clin Oncol. 2010 Jun;6(2):10.1111/j.1743-7563.2010.01290.x. doi: 10.1111/j.1743-7563.2010.01290.x

Table 1.

Description of phase II clinical trials used in the pooled analysis of carbohydrate antigen 19-9 (CA19-9) measurements and patient outcome

Study description Period No. of patients in the study Patients with baseline CA19-9 value Patients with CA19-9 at baseline and after one cycle of chemotherapy
Gemcitabine and cisplatin20 May 1997 to March 1999 42 40 30
Gemcitabine, cisplatin and 5-FU21 April 1999 to November 2001 47 43 27
Gemcitabine, celecoxib and cisplatin22 January 2002 to May 2003 22 19 11
Total 111 102 68